Partnering is an integral part of our strategy at Vernalis. We actively in-license and out-license programmes as well as enter into research and development collaborations. We seek to in-license late-stage, low risk assets that will complement our cough cold commercial strategy in the US, illustrated by our acquisition of the US rights to Moxatag®.
- In-licensing opportunities sought to complement our US commercial strategy
- Promising candidates ready for out-licensing now
- Research partnerships